GlassScriptPhysician profile
Naresh Menezes
NPI 1306814694
$6,153.47
in general payments reported to CMS, 2019-2025
47 companies · $779 in 2025
The $779 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,163 · 2020: $680 · 2021: $1,174 · 2022: $497 · 2023: $1,002 · 2024: $859 · 2025: $779.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,640.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,639.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $617.67 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Novo Nordisk INC | $605.38 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $562.55 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Janssen Pharmaceuticals, INC | $483.86 | 2019-2023 | Xarelto |
| Pfizer INC. | $400.74 | 2019-2025 | |
| Glaxosmithkline, LLC. | $373.90 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $333.88 | 2019-2025 | Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $237.00 | 2019-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $217.31 | 2019-2021 | |
| Amarin Pharma, INC. | $212.20 | 2019-2021 | |
| Organogenesis INC. | $207.67 | 2023-2025 | Novachor, Affinity, Puraply |
| Abbott Laboratories | $193.03 | 2022-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $156.82 | 2022-2024 | |
| Allergan, INC. | $141.05 | 2019-2020 | |
| Corcept Therapeutics | $132.75 | 2024-2025 | Korlym |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naresh Menezes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.